Skip navigation

FAST MONEY FEATURES

PollFast Money PollsFAST MONEY POLL
Get in the post game.  Respond to our
"Question of the Day" right now.


52 Week High52 Week High TRADER RADAR
Which stock should be on your screen? Follow the clues to solve this puzzle.



Trade SchoolTRADE SCHOOL
Grab a pencil because school is in session and the Fast Money traders are teaching class.


FAST MONEY EMERGING MONEY
EMERGING MONEY TOP 20
Fast Money's index for the world.




PodcastFM PodcastsFAST MONEY PODCASTS
Download Fast Money onto your MP3 Player.




FM WIDGETFAST MONEY WIDGET
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.



ShopSHOP FOR FAST MONEY MERCHANDISE
Get your game on with Fast Money gear.




Wanna See Our PhotosFAST MONEY PHOTOS!
Check out our scrapbook.  These "pix" are guaranteed winners.




SignupNewsletterNEWSLETTER
Sign up and receive a recap email every Friday after the show!





FM Mobile AlertFAST MONEY MOBILE ALERTS
Get advanced information about the next Fast Money.



Fast Money HomeFast Money Rapid RecapAbout Fast MoneyFast Money BiosFast Money Web ExtraFast Money Disclaimer
Text Size

Was Pfizer's miss, a prescription for disaster in Big Pharma? Should you sell drug makers ahead of earnings next week?

Pfizer [PFE  Loading...      ()   ]the world's biggest drugmaker, reported an 18 percent drop Thursday in its first-quarter profit on tougher generic competition but said it still expects to meet profit expectations for the full-year.

Its profit fell because of sharp declines in sales of the blood-pressure drug Norvasc and allergy drug Zyrtec. Both have lost patent protection and compete against cheaper, generic drugs. Wall Street expects the biggest blow to revenue in 2010, when sales of the world's best-selling drug Lipitor are sure to fall after it loses patent protection, explains Melissa Lee

Merck (MRK), Lilly (LLY) and Novartis (NVS) report earnings in the week ahead but I recommend watching Amylin (AMLN), counsels Pete Najarian. Their once a week diabetes drug could be huge for them. Also keep an eye on Biogen (BIIB).

The whole space terrifies me, exclaims Jeff Macke. I’d put my money in tech instead.

Bitter Pill?
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...



______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to .

Trader disclosure: On Apr. 18, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (DIS), (INTC), (MSFT), (YHOO); Najarian Owns (AAPL), (AMR), (BIIB), (CSCO), (MSFT), (NOK), (TSO), (XLF), (YHOO), (ETFC), (EMC), (NVS); Najarian Owns (BKC); Najarian Owns (BHI) Calls,  (BSC) Calls, (COP) Calls, (DD) Calls; Finerman Owns (GS); Finerman's Firm Owns (JCP), (MSFT), (NOK), (PZN), (TSO), (VCLK), (VLO), (YHOO), (GE), (NOK); Finerman's Firm Owns (FNM) Calls; Finerman's Firm Is Short (COF); Charles Schwab Is A Sponsor Of "Fast Money"; GE Is The Parent Company Of CNBC

© 2008 CNBC.com

Permalink: /id/24201959

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC MOBILE  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis